Invesco Ltd. Lowers Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Invesco Ltd. trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 63.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,691 shares of the company's stock after selling 97,911 shares during the quarter. Invesco Ltd. owned 0.07% of IDEAYA Biosciences worth $1,457,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of IDYA. R Squared Ltd purchased a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. boosted its position in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after buying an additional 853 shares during the period. KBC Group NV increased its position in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after acquiring an additional 1,923 shares during the period. Cibc World Markets Corp acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at $203,000. Finally, Aigen Investment Management LP purchased a new position in IDEAYA Biosciences in the fourth quarter valued at $280,000. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences Stock Up 2.2 %

IDYA traded up $0.46 on Friday, reaching $20.93. The company had a trading volume of 1,645,235 shares, compared to its average volume of 970,038. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $44.42. The stock has a market capitalization of $1.83 billion, a PE ratio of -6.34 and a beta of 0.26. The stock has a 50-day moving average price of $17.90 and a 200-day moving average price of $23.05.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on IDYA shares. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Stephens reiterated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.